Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alejandro Navarro

Showing results (81-90 of 101) with videos related to

Pageof 11
Sort By:
The Lancet. Oncology|August 14, 2019
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion studyMartin Schuler, Byoung Chul Cho, Cyrus Michael Sayehli, et al.
Cancers|July 29, 2023
Expression of TILs and Patterns of Gene Expression from Paired Samples of Malignant Pleural Mesothelioma (MPM) PatientsSusana Cedres, Garazi Serna, Alberto Gonzalez-Medina, et al.
Lung Cancer (Amsterdam, Netherlands)|March 12, 2022
Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancerMartin J Edelman, Mikhail Dvorkin, Konstatin Laktionov, et al.
Cancer|January 29, 2025
Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancerJacob M Sands, Stéphane Champiat, Horst-Dieter Hummel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2020
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 StudyCharles M Rudin, Mark M Awad, Alejandro Navarro, et al.
JTO Clinical and Research Reports|November 13, 2023
Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLCHye Ryun Kim, Mark M Awad, Alejandro Navarro, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 24, 2026
Corrigendum to 'Patient-Reported Outcomes With Consolidation Durvalumab Versus Placebo After Concurrent Chemoradiotherapy in Limited-Stage SCLC: Results From the Phase 3 ADRIATIC Trial' [Journal of Thoracic Oncology volume 21 issue 6 (2026) 103564]Silvia Novello, David R Spigel, Jian Fang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 1, 2026
Patient-Reported Outcomes with Consolidation Durvalumab Versus Placebo Following Concurrent Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer: Results from the Phase 3 ADRIATIC TrialSilvia Novello, Ying Cheng, David Spigel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 12, 2025
Lurbinectedin Plus Pembrolizumab in Relapsed SCLC: The Phase I/II LUPER StudyAntonio Calles, Alejandro Navarro, Bernard Gaston Doger de Speville Uribe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2023
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung CancerCharles M Rudin, Stephen V Liu, Ross A Soo, et al.
Pageof 11

Showing results (81-90 of 101) with videos related to

Sort By:
Pageof 11
The Lancet. Oncology|August 14, 2019
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion studyMartin Schuler, Byoung Chul Cho, Cyrus Michael Sayehli, et al.
Cancers|July 29, 2023
Expression of TILs and Patterns of Gene Expression from Paired Samples of Malignant Pleural Mesothelioma (MPM) PatientsSusana Cedres, Garazi Serna, Alberto Gonzalez-Medina, et al.
Lung Cancer (Amsterdam, Netherlands)|March 12, 2022
Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancerMartin J Edelman, Mikhail Dvorkin, Konstatin Laktionov, et al.
Cancer|January 29, 2025
Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancerJacob M Sands, Stéphane Champiat, Horst-Dieter Hummel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2020
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 StudyCharles M Rudin, Mark M Awad, Alejandro Navarro, et al.
JTO Clinical and Research Reports|November 13, 2023
Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLCHye Ryun Kim, Mark M Awad, Alejandro Navarro, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 24, 2026
Corrigendum to 'Patient-Reported Outcomes With Consolidation Durvalumab Versus Placebo After Concurrent Chemoradiotherapy in Limited-Stage SCLC: Results From the Phase 3 ADRIATIC Trial' [Journal of Thoracic Oncology volume 21 issue 6 (2026) 103564]Silvia Novello, David R Spigel, Jian Fang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 1, 2026
Patient-Reported Outcomes with Consolidation Durvalumab Versus Placebo Following Concurrent Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer: Results from the Phase 3 ADRIATIC TrialSilvia Novello, Ying Cheng, David Spigel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 12, 2025
Lurbinectedin Plus Pembrolizumab in Relapsed SCLC: The Phase I/II LUPER StudyAntonio Calles, Alejandro Navarro, Bernard Gaston Doger de Speville Uribe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2023
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung CancerCharles M Rudin, Stephen V Liu, Ross A Soo, et al.
Pageof 11